Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis

Michael J. Brennan*, Bartholt Clagett, Hillary Fitzgerald, Vicki Chen, Ann Williams, Angelo A. Izzo, Lewellys F. Barker

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    55 Citations (Scopus)


    In this review, published peer-reviewed preclinical studies using prime-boost tuberculosis (TB) vaccine regimens in animal challenge models for tuberculosis have been evaluated. These studies have been divided into groups that describe prime-boost vaccine combinations that performed better than, equivalent to, or worse than the currently used BCG vaccine. Review of the data has revealed interesting findings, including that more than half of the published studies using BCG as a prime combined with a novel boost vaccine give better efficacy than BCG alone and that the greatest reduction in Mycobacterium tuberculosis (M.tb.) colonization of animal tissues is provided by viral vectored vaccines delivered intranasally. Careful evaluation of these data should assist in defining the value of prime-boost regimens for advancement into human TB vaccine trials and stimulate the development of criteria for choosing which vaccine candidates should be studied further.

    Original languageEnglish
    Pages (from-to)2811-2823
    Number of pages13
    Issue number18
    Publication statusPublished - 16 Apr 2012

    Bibliographical note

    Funding Information:
    We thank Ann Ginsberg and Dominick Laddy of Aeras for a critical reading of the manuscript. Aeras acknowledges the support from a number of private foundations and governments, including the Bill & Melinda Gates Foundation, the UK Department for International Development, and the Dutch Ministry of Foreign Affairs. A.A.I. is supported by NIH , NIAID contracts HHSN266200400091c and HHSN272201000009I-003.

    Copyright 2021 Elsevier B.V., All rights reserved.


    • Animal models
    • Tuberculosis
    • Vaccines


    Dive into the research topics of 'Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis'. Together they form a unique fingerprint.

    Cite this